JP2019529406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019529406A5 JP2019529406A5 JP2019514088A JP2019514088A JP2019529406A5 JP 2019529406 A5 JP2019529406 A5 JP 2019529406A5 JP 2019514088 A JP2019514088 A JP 2019514088A JP 2019514088 A JP2019514088 A JP 2019514088A JP 2019529406 A5 JP2019529406 A5 JP 2019529406A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- formula
- nucleotide
- oligonucleotide according
- nucleotides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021176346A JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2022175211A JP7478210B2 (ja) | 2016-09-14 | 2022-11-01 | 修飾オリゴヌクレオチド及び使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394739P | 2016-09-14 | 2016-09-14 | |
| US201662394738P | 2016-09-14 | 2016-09-14 | |
| US62/394,739 | 2016-09-14 | ||
| US62/394,738 | 2016-09-14 | ||
| PCT/US2017/051644 WO2018053185A1 (en) | 2016-09-14 | 2017-09-14 | Modified oligonucleotides and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021176346A Division JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019529406A JP2019529406A (ja) | 2019-10-17 |
| JP2019529406A5 true JP2019529406A5 (enExample) | 2020-10-22 |
| JP6970187B2 JP6970187B2 (ja) | 2021-11-24 |
Family
ID=59955744
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019514088A Expired - Fee Related JP6970187B2 (ja) | 2016-09-14 | 2017-09-14 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2021176346A Active JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2022175211A Active JP7478210B2 (ja) | 2016-09-14 | 2022-11-01 | 修飾オリゴヌクレオチド及び使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021176346A Active JP7170820B2 (ja) | 2016-09-14 | 2021-10-28 | 修飾オリゴヌクレオチド及び使用方法 |
| JP2022175211A Active JP7478210B2 (ja) | 2016-09-14 | 2022-11-01 | 修飾オリゴヌクレオチド及び使用方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US10793859B2 (enExample) |
| EP (1) | EP3512949A1 (enExample) |
| JP (3) | JP6970187B2 (enExample) |
| KR (3) | KR102627418B1 (enExample) |
| CN (1) | CN109952378B (enExample) |
| AU (2) | AU2017326372B2 (enExample) |
| BR (1) | BR112019004911A2 (enExample) |
| CA (1) | CA3037042A1 (enExample) |
| IL (2) | IL265359B2 (enExample) |
| MA (1) | MA46422A (enExample) |
| MX (2) | MX2019002960A (enExample) |
| TW (1) | TWI769177B (enExample) |
| WO (1) | WO2018053185A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019002960A (es) | 2016-09-14 | 2019-09-18 | Janssen Biopharma Inc | Oligonucleótidos modificados y métodos de uso. |
| AU2018332214B2 (en) * | 2017-09-14 | 2023-11-02 | Janssen Biopharma, Inc. | Modified nucleoside phosphoramidites |
| CN111527207B (zh) * | 2017-09-14 | 2024-04-26 | 詹森生物制药有限公司 | GalNAc衍生物 |
| WO2020097342A1 (en) * | 2018-11-08 | 2020-05-14 | Aligos Therapeutics, Inc. | S-antigen transport inhibiting oligonucleotide polymers and methods |
| WO2021198958A1 (en) * | 2020-04-01 | 2021-10-07 | Janssen Biopharma, Inc. | Nucleic acid polymers |
| US20220056451A1 (en) * | 2020-07-27 | 2022-02-24 | Aligos Therapeutics, Inc. | Hbv binding oligonucleotides and methods of use |
| CN114057816B (zh) * | 2020-07-30 | 2025-02-11 | 浙江柏拉阿图医药科技有限公司 | 富含腺嘌呤硫代磷酸酯化寡核苷酸及其抗肝炎病毒的应用 |
| JP7517475B2 (ja) | 2021-01-12 | 2024-07-17 | 日本電気株式会社 | 秘密計算システム、秘密計算サーバ装置、秘密計算方法および秘密計算プログラム |
| TW202340468A (zh) | 2022-01-10 | 2023-10-16 | 中國大陸商杭州浩博醫藥有限公司 | B型肝炎病毒(hbv)表現之調節 |
| TW202508607A (zh) * | 2023-05-19 | 2025-03-01 | 大陸商北京炫景瑞醫藥科技有限公司 | 雙股寡核苷酸及其共軛物和用途 |
| US20250345389A1 (en) * | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002081494A1 (en) | 2001-03-26 | 2002-10-17 | Sirna Therapeutics, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
| JP3482209B2 (ja) | 1994-03-18 | 2003-12-22 | ジェロン・コーポレーション | オリゴヌクレオチドｎ３’→ｐ５’ホスホルアミデート：合成および化合物；ハイブリダイゼーションおよびヌクレアーゼ耐性特性 |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| KR100573231B1 (ko) | 1999-02-12 | 2006-04-24 | 상꾜 가부시키가이샤 | 신규 뉴클레오시드 및 올리고뉴클레오티드 유사체 |
| US7084125B2 (en) | 1999-03-18 | 2006-08-01 | Exiqon A/S | Xylo-LNA analogues |
| AU776362B2 (en) | 1999-05-04 | 2004-09-09 | Roche Innovation Center Copenhagen A/S | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| JP4151751B2 (ja) | 1999-07-22 | 2008-09-17 | 第一三共株式会社 | 新規ビシクロヌクレオシド類縁体 |
| DK1210357T3 (da) * | 1999-09-10 | 2008-07-21 | Geron Corp | Oligonukleotid-N3' -P5' -thiophosphoramidater: syntese og anvendelse deraf |
| WO2001053307A1 (en) | 2000-01-21 | 2001-07-26 | Geron Corporation | 2'-arabino-fluorooligonucleotide n3'→p5'phosphoramidates: their synthesis and use |
| US7563618B2 (en) * | 2001-03-23 | 2009-07-21 | Geron Corporation | Oligonucleotide conjugates |
| US7569575B2 (en) | 2002-05-08 | 2009-08-04 | Santaris Pharma A/S | Synthesis of locked nucleic acid derivatives |
| US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
| EP1562971B1 (en) | 2002-11-05 | 2014-02-12 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2005003314A2 (en) * | 2003-06-27 | 2005-01-13 | Isis Pharmaceuticals, Inc. | A method of selecting an active oligonucleotide predictive model |
| US9133233B2 (en) | 2003-11-04 | 2015-09-15 | Geron Corporation | RNA amidates and thioamidates for RNAi |
| CA2619876A1 (en) * | 2005-08-17 | 2007-02-22 | Sirna Therapeutics, Inc. | Chemically modified short interfering nucleic acid molecules that mediate rna interference |
| WO2008011473A2 (en) * | 2006-07-19 | 2008-01-24 | Isis Pharmaceuticals, Inc. | Compositions and their uses directed to hbxip |
| KR20120095397A (ko) * | 2009-10-16 | 2012-08-28 | 글락소 그룹 리미티드 | Ｈｂｖ 안티센스 억제제 |
| WO2011060557A1 (en) | 2009-11-20 | 2011-05-26 | Governors Of The University Of Alberta | Method for selection of aptamers |
| WO2011139911A2 (en) * | 2010-04-29 | 2011-11-10 | Isis Pharmaceuticals, Inc. | Lipid formulated single stranded rna |
| MX347253B (es) * | 2011-04-21 | 2017-04-20 | Ionis Pharmaceuticals Inc | Modulación de la expresión del virus de hepatitis b (vhb). |
| SG194751A1 (en) * | 2011-06-30 | 2013-12-30 | Arrowhead Res Corp | Compositions and methods for inhibiting gene expression of hepatitis b virus |
| WO2013159109A1 (en) | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Modulation of hepatitis b virus (hbv) expression |
| US9403865B2 (en) * | 2012-08-15 | 2016-08-02 | Ionis Pharmaceuticals, Inc. | Method of preparing oligomeric compounds using modified capping protocols |
| US9228189B2 (en) * | 2012-10-26 | 2016-01-05 | Geron Corporation | C-myc antisense oligonucleotides and methods for using the same to treat cell-proliferative disorders |
| JOP20200092A1 (ar) * | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
| US10059940B2 (en) * | 2015-01-27 | 2018-08-28 | Minghong Zhong | Chemically ligated RNAs for CRISPR/Cas9-lgRNA complexes as antiviral therapeutic agents |
| MX2019002960A (es) | 2016-09-14 | 2019-09-18 | Janssen Biopharma Inc | Oligonucleótidos modificados y métodos de uso. |
-
2017
- 2017-09-14 MX MX2019002960A patent/MX2019002960A/es unknown
- 2017-09-14 JP JP2019514088A patent/JP6970187B2/ja not_active Expired - Fee Related
- 2017-09-14 KR KR1020237006131A patent/KR102627418B1/ko active Active
- 2017-09-14 AU AU2017326372A patent/AU2017326372B2/en active Active
- 2017-09-14 CA CA3037042A patent/CA3037042A1/en active Pending
- 2017-09-14 WO PCT/US2017/051644 patent/WO2018053185A1/en not_active Ceased
- 2017-09-14 TW TW106131624A patent/TWI769177B/zh active
- 2017-09-14 IL IL265359A patent/IL265359B2/en unknown
- 2017-09-14 KR KR1020197010486A patent/KR102533038B1/ko active Active
- 2017-09-14 US US15/705,137 patent/US10793859B2/en active Active
- 2017-09-14 EP EP17772270.9A patent/EP3512949A1/en active Pending
- 2017-09-14 KR KR1020247001776A patent/KR20240010761A/ko not_active Abandoned
- 2017-09-14 CN CN201780070383.1A patent/CN109952378B/zh active Active
- 2017-09-14 MA MA046422A patent/MA46422A/fr unknown
- 2017-09-14 BR BR112019004911A patent/BR112019004911A2/pt not_active Application Discontinuation
- 2017-09-14 IL IL315071A patent/IL315071A/en unknown
-
2019
- 2019-03-13 MX MX2023014145A patent/MX2023014145A/es unknown
-
2020
- 2020-10-05 US US17/063,080 patent/US12077757B2/en active Active
-
2021
- 2021-10-28 JP JP2021176346A patent/JP7170820B2/ja active Active
-
2022
- 2022-11-01 JP JP2022175211A patent/JP7478210B2/ja active Active
-
2024
- 2024-03-06 AU AU2024201485A patent/AU2024201485A1/en active Pending
- 2024-08-06 US US18/795,672 patent/US20250092400A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019529406A5 (enExample) | ||
| KR102540359B1 (ko) | B형 간염 바이러스 감염에 대한 RNAi 작용제 | |
| JP2023011793A5 (enExample) | ||
| JP2020072724A5 (enExample) | ||
| JP2019062913A5 (enExample) | ||
| US12503698B2 (en) | GalNAc derivatives | |
| JP2010519915A5 (enExample) | ||
| IL315071A (en) | Modified oligonucleotides and pharmaceutical compositions | |
| JP2017079759A5 (enExample) | ||
| JP2018199700A5 (enExample) | ||
| JP2016533761A5 (enExample) | ||
| JP2020503010A5 (enExample) | ||
| JP2009532044A5 (enExample) | ||
| JP2011502501A5 (enExample) | ||
| JPWO2021178885A5 (enExample) | ||
| JP2023138687A (ja) | Ｂ型肝炎感染の治療用のＰＡＰＤ５及びＰＡＰＤ７ ｍＲＮＡを低減させるための核酸分子 | |
| KR20210130736A (ko) | B형 간염 바이러스 감염에 대한 RNAi 작용제 | |
| BR112020020220A2 (pt) | Uso de inibidores da fubp1 para o tratamento de infecção pelo vírus da hepatite b | |
| JP2019512498A5 (enExample) | ||
| JP2021505129A5 (enExample) | ||
| JP2013513360A5 (enExample) | ||
| JP2018538302A5 (enExample) | ||
| JP2017518966A5 (enExample) | ||
| JP2019534025A (ja) | 治療用オリゴヌクレオチドの捕捉および検出 | |
| JP2018525015A5 (enExample) |